Today's stock news 18/09/2026: Gubra, GomSpace and Flügger
Summary
- Gubra's partner, Hemab Therapeutics, has commenced a Phase 1 clinical trial for HMB-003, a plasmin inhibitor for heavy menstrual bleeding, marking progress in their partnership initiated in 2023.
- GomSpace announced a multi-phased partnership with a new EMEA customer, valued initially at MEUR 3.8, covering satellite missions and services, with potential for further phases.
- Flügger is set to release its Q1 2026/27 interim report on September 30, with expected revenue growth driven by the Polish market, while Denmark remains flat due to the phase-out of private labels.
This content is generated by AI. You can give feedback on it in the Inderes forum.
Automatic translation: Originally published in Danish 18/09/2026, 07:00 GMT. Give feedback here.
Gubra announced yesterday that its partner Hemab Therapeutics has dosed the first healthy subject in a Phase 1 clinical trial of HMB-003, a peptide-based plasmin inhibitor targeting heavy menstrual bleeding. The trial (NCT07798505) is a randomized, placebo-controlled ascending single-dose study designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics. HMB-003 stems from a partnership initiated in 2023 combining Gubra's streaMLine platform with Hemab's expertise in bleeding disorders, with Hemab holding full responsibility for development and monetization. The financial terms of the agreement have not been disclosed, meaning the program is not a standalone value driver in the investment case, which continues to rely on ABBV-295 (AbbVie), BI 3034701 (Boehringer Ingelheim), and the wholly owned GUB-UCN2. Nevertheless, the news highlights two key takeaways for the share: Gubra is delivering on its announced timeline for FIH start in H2 2026, and yet another molecule from the platform is reaching the clinical phase outside the obesity domain. This supports the argument for a disease-agnostic platform with multiple potential milestone and royalty streams over time. Hemab is preparing clinical trials in heavy menstrual bleeding in 2027, while the next actual share price catalysts for Gubra include the ABBV-295 presentation at EASD on September 30 and the company's R&D event in late October. GomSpace announced this morning a multi-phased partnership agreement with a new commercial customer in the EMEA region within advanced systems and critical technology. The initial phase is valued at MEUR 3.8, corresponding to MSEK 42.2, with delivery from late 2026 through 2027. It covers satellite missions, mission services, platform kits, and standard products—spanning the entire business—and is structured with options for additional phases, much like the MSEK 81.5 VirtuaLabs agreement in Q1. This is precisely the type of multi-phased customer relationship with a new client that is expected to drive order intake into 2027. Read the full release here: https://www.inderes.dk/releases/gomspace-as-gomspace-signs-38-meur-multi-phased-partnership-agreement-with-european-space-company-specializing-in-advanced-systems-and-critical-technologyFlügger will publish its Q1 2026/27 interim report on Wednesday, September 30, which will solely disclose revenue broken down by segments and geography. We estimate revenue of MDKK 674, corresponding to growth of 3.2% vs. the same quarter last year, primarily driven by Poland, while Denmark is expected to be roughly flat as comparison figures continue to be impacted by the phase-out of private label. Our focus will be on whether the 12% growth in the number of professional painting customers in the Nordics in 2025/26 translates into reported revenue. Read our full comment here: https://www.inderes.dk/en/analyst-comments/flugger-q12627-preview-will-core-customer-growth-show-in-the-top-lineDisclaimer: HC Andersen Capital receives payment from the mentioned companies for a Digital IR subscription agreement. /Rasmus Køjborg, CFA on 18/09/2026 at 09:00 AM.